Ricardo Sánchez-Rodríguez

Ricardo Sánchez-Rodríguez

Auto-generated profile, based on publicly available information

Ricardo Sánchez-Rodríguez

Department of Biomedical Sciences, University of Padova

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RSRicardo Sánchez-Rodríguez
Ricardo Sánchez-Rodríguez
JTJulia Esperanza Torres-Mena
Julia Esperanza Torres-Mena
VQValeria Quintanar-Jurado
Valeria Quintanar-Jurado
VCVictoria Chagoya
Victoria Chagoya
EEmilio Rojas
Emilio Rojas
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon

30 January 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JTJulia Esperanza Torres-Mena
Julia Esperanza Torres-Mena
KSKarla Noemí Salazar-Villegas
Karla Noemí Salazar-Villegas
RSRicardo Sánchez-Rodríguez
Ricardo Sánchez-Rodríguez
BLBelém López-Gabiño
Belém López-Gabiño
LPLuis Del Pozo-Yauner
Luis Del Pozo-Yauner
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon

1 August 2014 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
RSRicardo Sánchez-Rodríguez
Ricardo Sánchez-Rodríguez
JTJulia Esperanza Torres-Mena
Julia Esperanza Torres-Mena
MDMonica De-La-Luz-Cruz
Monica De-La-Luz-Cruz
GBGloria Alejandra Bernal-Ramos
Gloria Alejandra Bernal-Ramos
SVSaúl Villa-Treviño
Saúl Villa-Treviño
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon

25 March 2021 in Molecular Carcinogenesis
Verified
Journal Article
Open access
PDF file
MCMaría Paulette Castro‐Gil
María Paulette Castro‐Gil
RSRicardo Sánchez‐Rodríguez
Ricardo Sánchez‐Rodríguez
JTJulia Esperanza Torres‐Mena
Julia Esperanza Torres‐Mena
CLCarlos David López‐Torres
Carlos David López‐Torres
VQValeria Quintanar‐Jurado
Valeria Quintanar‐Jurado
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon
The potential role of hepatocytes versus hepatic progenitor cells (HPC) on the onset and pathogenesis of hepatocellular carcinoma (HCC) has not been fully clarified. Because the administration of 2‐acetylaminofluorene (2AAF) followed by a partial hepatectomy, selectively induces the HPC proliferation, we investigated the effects of chronic 2AAF administration on the HCC development caused by the chronic administration of the carcinogen diethylnitrosamine (DEN) for 16 weeks in the rat. DEN + 2AAF protocol impeded weight gain of animals but promoted prominent hepatomegaly and exacerbated liver alterations compared to DEN protocol alone. The tumor areas detected by γ‐glutamyl transferase, prostaglandin reductase‐1, and glutathione S‐transferase Pi−1 liver cancer markers increased up to 80% as early as 12 weeks of treatment, meaning 6 weeks earlier than DEN alone. This protocol also increased the number of Ki67‐positive cells and those of CD90 and CK19, two well‐known progenitor cell markers. Interestingly, microarray analysis revealed that DEN + 2AAF protocol differentially modified the global gene expression signature and induced the differential expression of 30 genes identified as HPC markers as early as 6 weeks of treatment. In conclusion, 2AAF induces the early appearance of HPC markers and as a result, accelerates the hepatocarcinogenesis induced by DEN in the rat. Thus, since 2AAF simultaneously administrated with DEN enriches HPC during hepatocarcinogenesis, we propose that DEN + 2AAF protocol might be a useful tool to investigate the cellular origin of HCC with progenitor features.

1 February 2014 in Analytical Biochemistry
Verified
Journal Article
Closed access
JMJulia Esperanza Torres Mena
Julia Esperanza Torres Mena
RRRicardo Sánchez Rodríguez
Ricardo Sánchez Rodríguez
VJValeria Quintanar Jurado
Valeria Quintanar Jurado
RERaúl Mojica Espinosa
Raúl Mojica Espinosa
LYLuis Del Pozo Yauner
Luis Del Pozo Yauner
JPJulio Isael Perez-Carreon
Julio Isael Perez-Carreon

24 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RAR. Angioni
R. Angioni
MBM. Bonfanti
M. Bonfanti
NCN. Caporale
N. Caporale
RSR. Sánchez-Rodríguez
R. Sánchez-Rodríguez
FMF. Munari
F. Munari
GTG. Testa
G. Testa
The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.